Achondroplasia in Children and Adolescents
Ascendis Pharma Growth Disorders A/S focuses its clinical research on achondroplasia across pediatric age groups, with studies centered on growth, linear growth, and the clinical needs of affected children and adolescents.
- Growth outcomes
- Pediatric skeletal dysplasia
- Children with achondroplasia
The sponsor’s research activity includes both younger and older pediatric populations, reflecting a sustained interest in the treatment of growth disorders associated with this condition.
Growth-Targeted Therapeutics
The clinical portfolio includes investigational work on navepegritide and TransCon CNP, with a therapeutic emphasis on supporting growth in individuals with achondroplasia.
- Linear growth
- Growth promotion
- C-type natriuretic peptide pathway
These studies place endocrine and skeletal growth mechanisms at the center of the sponsor’s research interests.
Combination Approaches in Growth Disorder Care
Research also extends to combined use of navepegritide with lonapegsomatropin, indicating interest in therapeutic strategies for improving height gain and growth response in pediatric achondroplasia.
- Combination therapy
- Somatropin-based treatment
- Pediatric height development
This area reflects attention to treatment options that address the clinical burden of short stature in affected patients.
Safety, Tolerability, and Long-Term Use
Several trials examine the safety, tolerability, and sustained use of TransCon CNP and navepegritide in pediatric populations with achondroplasia.
- Long-term treatment
- Pediatric safety
- Chronic growth management
The sponsor’s research interests include ongoing evaluation of treatment use over extended periods in children and adolescents.
